Top Midday Gainers

MT Newswires24minutes ago

Scholar Rock Hits 3-Year High on Rival Biohaven's Drug Setback

Reuters11:56 ET

Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study

Benzinga11:51 ET

Biohaven Outcome 'Fundamental Net Positive' for Scholar Rock, Says JPMorgan

TipRanks11:40 ET

Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro

Reuters11:34 ET

Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating, Announces Target Price $45

Moomoo News11:31 ET · Ratings